Introduction: Medical management is a keystone in managing symptomatic fibroids. Availability of an effective, safe, and costeffective medical treatment should always be considered as an alternative to reduce the cost, morbidity, and impact of avoidable major surgeries. Objective: To study the effect of 10 mg Mifepristone on symptomatic fibroids. Materials and methods: This prospective study was conducted at a tertiary care center in Raipur. Fifty women of the reproductive age group with symptomatic uterine fibroids with normal liver and kidney function tests were recruited. A total of 10 mg of oral Mifepristone was administered daily for 3 months. Monthly symptomatic assessment, ultrasonography, and biochemical parameters were done to assess changes. Results: There was significant reduction in menstrual blood loss (MBL) and associated symptoms. Amenorrhea occurred in 100% of women after 3 months of treatment. The fibroid volume and mean uterine size reduced by 26.2 and 26.99% respectively. Mean hemoglobin levels increased by 1.93 gm/dL. Observed side effects were few and tolerable. Conclusion: Mifepristone is an effective and safe alternative for the management of leiomyoma.